Search terms
Results 1 - 5 of 5 - ordered by :

Abstract Aim Differential drug treatment guided by the underlying heart disease may improve outcome of rhythm control therapy. In the present study we investigated in a well-defined group with ...

Europace, Regular Article, Trudeke Van Noord, Robert G. Tieleman, Hans A. Bosker, Tsjerk Kingma, Dirk J. Van Veldhuisen, Harry J.G.M Crijns, Isabelle C. Van Gelder

Date : 01/01/2004 Item size : 226294 bytes

Introduction Atrial fibrillation (AF) is the most common cardiac arrhythmia, having a prevalence of 1% in young patients up to 9% in patients at the age of 75 years.1 It is estimated that the ...

Cardiovascular Research, REVIEWS: FOCUS ON THE MOLECULAR BASIS OF ATRIAL FIBRILLATION, Anne Margreet De Jong, Alexander H. Maass, Silke U. Oberdorf-Maass, Dirk J. Van Veldhuisen, Wiek H. Van Gilst, ...

Date : 01/03/2011 Item size : 631934 bytes

Episodic Prophylactic Treatment with Amiodarone for the Prevention of AF (CONVERT) study, using the Short Form (SF)-36 health survey and University of Toronto AF Severity Scale (AF severity scale) ...

Europace, Atrial Fibrillation - Clinical Issues, Sheba Ahmed, Adelita V. Ranchor, Harry J.G.M. Crijns, Dirk J. Van Veldhuisen, Isabelle C. Van Gelder, for the CONVERT investigators

Date : 01/06/2010

Outcome of pharmacological rhythm control for new-onset persistent atrial fibrillation in patients with systolic heart failure: a comparison with patients with normal left ventricular ...

Europace, ANTIARRHYTHMIC DRUGS, Martin E.W. Hemels, Ans C.P. Wiesfeld, Dirk J. Van Veldhuisen, Maarten P. Van den Berg, Isabelle C. Van Gelder

Date : 01/04/2007

Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro)BNP Abstract Aims To study the determinants of ...

Europace, FOCUS ON ATRIAL ARRHYTHMIAS, Michiel Rienstra, Isabelle C. Van Gelder, Maarten P. Van den Berg, Frans Boomsma, Dirk J. Van Veldhuisen

Date : 01/07/2006